{"id":"interferon-alfa-2a-roferon","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"70","effect":"Headache"},{"rate":"60-70","effect":"Myalgia"},{"rate":"50-60","effect":"Anorexia"},{"rate":"40-50","effect":"Nausea"},{"rate":"30-50","effect":"Leukopenia"},{"rate":"20-30","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Depression/mood changes"},{"rate":"5-10","effect":"Thyroid dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon alfa-2a is a cytokine that binds to type I interferon receptors (IFNAR1/IFNAR2) on immune and tumor cells, triggering intracellular signaling cascades that upregulate antiviral and anti-proliferative genes. This leads to increased expression of MHC molecules, enhanced cytotoxic T-cell and natural killer cell activity, and direct anti-proliferative effects on malignant cells. The drug also has immunomodulatory effects that enhance the host's innate and adaptive immune responses.","oneSentence":"Interferon alfa-2a activates the immune system by binding to interferon-alpha receptors on cell surfaces, enhancing natural killer cell and macrophage activity to fight viral infections and cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:28.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML)"},{"name":"Hairy cell leukemia"},{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"},{"name":"Melanoma (adjuvant therapy)"},{"name":"Kaposi sarcoma"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":694,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Interferon alfa 2a [Roferon]","genericName":"Interferon alfa 2a [Roferon]","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon alfa-2a activates the immune system by binding to interferon-alpha receptors on cell surfaces, enhancing natural killer cell and macrophage activity to fight viral infections and cancer cells. Used for Chronic myeloid leukemia (CML), Hairy cell leukemia, Chronic hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}